Computational modeling of human oral bioavailability: what will be next?

References

• Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. Nature Publishing Group. 2015;14(7):475–486.
   Google Scholar
• Kubinyi H. Drug research: myths, hype and reality. Nat Rev Drug Discov. 2003;2(8):665–668.
   PubMed Web of Science ®Google Scholar
• Pritchard JF, Jurima-Romet M, Reimer ML, et al. Making better drugs: decision gates in non-clinical drug development. Nat Rev Drug Discov. 2003;2(7):542–553.
   PubMed Web of Science ®Google Scholar
• Cabrera-Pérez MA, Pham-The H, Bermejo M, et al. QSPR in oral bioavailability: specificity or integrality? Mini Rev Med Chem. 2012;12(6):534–550.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang J, Yu H, et al. Recent developments of in silico predictions of oral bioavailability. Comb Chem High Throughput Screen. 2011;14(5):362–374.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 20 Jan 2010. London; European Medicines Agency (EMA). 2000.
   Google Scholar
• Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev. 1999;51(2):135–158.
   PubMed Web of Science ®Google Scholar
• Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol. 2001;5(4):452–463.
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Zhang W, et al. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J Chem Inf Model. 2007;47(1):208–218.
   PubMed Web of Science ®Google Scholar
• Wang J, Hou T. Advances in computationally modeling human oral bioavailability. Adv Drug Deliv Rev. 2015;86:11–16.
   PubMed Web of Science ®Google Scholar
• Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Suppl 1):S41–S67.
   PubMed Web of Science ®Google Scholar
• Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inf. 2010;29(6–7):476–488.
   PubMed Web of Science ®Google Scholar
• Canault B, Bourg S, Vayer P, et al. Comprehensive network map of ADME-Tox databases. Mol Inform. 2017;36:1–8.
   Web of Science ®Google Scholar
• Hirono S, Nakagome I, Hirano H, et al. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: oral bioavailability. Biol Pharm Bull. 1994;17(2):306–309.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210–258.
   PubMed Web of Science ®Google Scholar
• Pintore M, Van De Waterbeemd H, Piclin N, et al. Prediction of oral bioavailability by adaptive fuzzy partitioning. Eur J Med Chem. 2003;38(4):427–431.
   PubMed Web of Science ®Google Scholar
• Turner JV, Glass BD, Agatonovic-Kustrin S. Prediction of drug bioavailability based on molecular structure. Anal Chim Acta. 2003;485:89–102.
   Web of Science ®Google Scholar
• Turner JV, Maddalena DJ, Agatonovic-Kustrin S. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm Res. 2004;21(1):68–82.
   PubMed Web of Science ®Google Scholar
• Wang J, Krudy G, Xie XQ, et al. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion. J Chem Inf Model. 2006;46(6):2674–2683.
   PubMed Web of Science ®Google Scholar
• Moda TL, Montanari CA, Andricopulo AD. Hologram QSAR model for the prediction of human oral bioavailability. Bioorg Med Chem. 2007;15(24):7738–7745.
   PubMed Web of Science ®Google Scholar
• Ma CY, Yang SY, Zhang H, et al. Prediction models of human plasma protein binding rate and oral bioavailability derived by using GA-CG-SVM method. J Pharm Biomed Anal. 2008;47(4–5):677–682.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang W, Huang C, et al. A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci. 2012;13(6):6964–6982.
   PubMed Web of Science ®Google Scholar
• Olivares-Morales A, Hatley OJD, Turner D, et al. The use of roc analysis for the qualitative prediction of human oral bioavailability from animal data. Pharm Res. 2014;31(3):720–730.
   PubMed Web of Science ®Google Scholar
• Musther H, Olivares-Morales AA, Hatley OJD, et al. Animal versus human oral drug bioavailability: do they correlate? Eur J Pharm Sci. 2013;57(100):280–291.
   PubMedGoogle Scholar
• Olah M, Halip L, Hădărugă N, et al. Chemical Informatics: WOMBAT and WOMBAT-PK: Bioactivity Databases for Lead and Drug Discovery. In: Schreiber SL, Kapoor T, Wess G, editors. Chemical Biology: From Small Molecules to Systems Biology and Drug Design. Weinheim, Germany: Wiley VCH Verlag GmbH & Co. 2007:760–786.
   Google Scholar
• Cabrera-Pérez MÁ, González-Álvarez I. Computational and pharmacoinformatic approaches to oral bioavailability prediction. In: Hu M, Li X, editors. Oral bioavailability: basic principles, advanced concepts, and applications. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2011: 519–534.
   Google Scholar
• Hou T, Wang J, Zhang W, et al. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J Chem Inf Model. 2007;47(2):460–463.
   PubMed Web of Science ®Google Scholar
• Tian S, Li Y, Wang J, et al. ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints. Mol Pharm. 2011;8(3):841–851.
   PubMedGoogle Scholar
• Sietsema WK. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol. 1989;27(4):179–211.
   PubMedGoogle Scholar
• Zhao YH, Le J, Abraham MH, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci. 2001;90(6):749–784.
   PubMed Web of Science ®Google Scholar
• Moda TL, Torres LG, Carrara AE, et al. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics. 2008;24(19):2270–2271.
   PubMed Web of Science ®Google Scholar
• Cao D, Wang J, Zhou R, et al. ADMET evaluation in drug discovery. 11. Pharmacokinetics knowledge base (PKKB): a comprehensive database of pharmacokinetic and toxic properties for drugs. J Chem Inf Model. 2012;52:1132–1137.
   PubMed Web of Science ®Google Scholar
• Todeschini R, Consonni V. Handbook of molecular descriptors. Weinheim, Germany: Wiley VCH; 2000.
   Google Scholar
• Norinder U, Bergstrom CA. Prediction of ADMET properties. ChemMedChem. 2006;1(9):920–937.
   PubMed Web of Science ®Google Scholar
• OECD. Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models. OECD series on testing and assessment no. 69. ENV/JM/MONO(2007)2. Paris, France: Organisation for Economic Cooperation and Development; 2007.
   Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–2623.
   PubMed Web of Science ®Google Scholar
• Martin YC. A bioavailability score. J Med Chem. 2005;48(9):3164–3170.
   PubMed Web of Science ®Google Scholar
• Varma MV, Obach RS, Rotter C, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53(3):1098–1108.
   PubMed Web of Science ®Google Scholar
• Kier LB, Hall LH. An electrotopological-state index for atoms in molecules. Pharm Res. 1990;7(8):801–807.
   PubMed Web of Science ®Google Scholar
• Estrada E. How the parts organize in the whole? A top-down view of molecular descriptors and properties for QSAR and drug design. Mini Rev Med Chem. 2008;8(3):213–221.
   PubMed Web of Science ®Google Scholar
• Tao L, Zhang P, Qin C, et al. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. Adv Drug Deliv Rev. 2015;86:83–100.
   PubMed Web of Science ®Google Scholar
• Ursu O, Rayan A, Goldblum A, et al. Understanding drug-likeness. WIREs Comput Mol Sci. 2011;1:760–781.
   Google Scholar
• Doak BCC, Over BB, Giordanetto F, et al. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol. 2014;21(9):1115–1142.
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Kihlberg J. Macrocyclic drugs and clinical candidates what can medicinal chemists learn from their properties. J Med Chem. 2014;57(2):278–295.
   PubMed Web of Science ®Google Scholar
• Pham-The H, González-Álvarez I, Bermejo M, et al. The use of rule-based and QSPR approaches in adme profiling: a case study on caco-2 permeability. Mol Inform. 2013;32(5–6):459–479.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Crimin K, Goodwin JT, et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem. 2004;47:6104–6107.
   PubMed Web of Science ®Google Scholar
• Yoshida F, Topliss JG. QSAR model for drug human oral bioavailability. J Med Chem. 2000;43(13):2575–2585.
   PubMed Web of Science ®Google Scholar
• Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm Res. 2000;17(6):639–644.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yan A, Yuan Q, et al. Explorations into modeling human oral bioavailability. Eur J Med Chem. 2008;43(11):2442–2452.
   PubMed Web of Science ®Google Scholar
• Imawaka H, Ito K, Kitamura Y, et al. Prediction of human bioavailability from human oral administration data and animal pharmacokinetic data without data from intravenous administration of drugs in humans. Pharm Res. 2009;26(8):1881–1889.
   PubMedGoogle Scholar
• Hou T, Wang J. Structure-ADME relationship: still a long way to go? Expert Opin Drug Metab Toxicol. 2008;4(6):759–770.
   PubMed Web of Science ®Google Scholar
• Peters SA. Physiologically-based pharmacokinetic (PBPK) modeling and simulations. principles, methods, and applications in the pharmaceutical industry. New Jersey: John Wiley & Sons, Inc; 2012.
   Google Scholar
• Bouzom F, Ball K, Perdaems N, et al. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos. 2012;33:55–71.
   PubMed Web of Science ®Google Scholar
• Lin L, Wong H. Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models. Pharmaceutics. 2017;9(41):1–14.
   Google Scholar
• Espié P, Tytgat D, Sargentini-Maier M-L, et al. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev. 2009;41(3):391–407.
   PubMed Web of Science ®Google Scholar
• Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett. 2003;138(1–2):29–49.
   PubMed Web of Science ®Google Scholar
• Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet. 2008;47(4):261–275.
   PubMed Web of Science ®Google Scholar
• Jones HM, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–262.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Chung J, Asperen JV, et al. Physiologically based absorption modeling to impact biopharmaceutics and formulation strategies in drug development d industry case studies. J Pharm Sci. 2016;105(9):2723–2734.
   PubMed Web of Science ®Google Scholar
• Huang SM, Abernethy DR, Wang Y, et al. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 2013;102(9):2912–2923.
   PubMed Web of Science ®Google Scholar
• Dokoumetzidis A, Valsami G, Macheras P. Modelling and simulation in drug absorption processes. Xenobiotica. 2007;37:1052–1065.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119–125.
   PubMed Web of Science ®Google Scholar
• Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 1999;16(12):1883–1887.
   PubMed Web of Science ®Google Scholar
• Parrott N, Paquereau N, Coassolo P, et al. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci. 2005;94(10):2327–2343.
   PubMed Web of Science ®Google Scholar
• Paixao P, Gouveia LF, Morais JAG. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. Int J Pharm. 2012;429:84–98.
   PubMed Web of Science ®Google Scholar
• Thelen K, Coboeken K, Willmann S, et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 2011;100(12):5324–5345.
   PubMed Web of Science ®Google Scholar
• Thelen K, Coboeken K, Willmann S, et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part ii: extension to describe performance of solid dosage forms. J Pharm Sci. 2012;101(3):1267–1280.
   PubMed Web of Science ®Google Scholar
• Jamei M, Turner D, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. Aaps J. 2009;11(2):225–237.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Neuhoff S, Jamei M, et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model. Curr Drug Deliv. 2010;11:716–729.
   Google Scholar
• Cai H, Stoner C, Reddy A, et al. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. Int J Pharm. 2006;308(1–2):133–139.
   PubMedGoogle Scholar
• Daga PR, Bolger MB, Haworth IS, et al. Physiologically-based pharmacokinetic modeling in lead optimization I: evaluation and adaptation of gastroplus to predict bioavailability of medchem series. Mol Pharm. 2018;15:821–830.
   PubMedGoogle Scholar
• Olivares-Morales A, Ghosh A, Aarons L, et al. Development of a novel simplified PBPK absorption model to explain the higher relative bioavailability of the oros ® formulation of oxybutynin. Aaps J. 2016;18(6):1532–1549.
   PubMed Web of Science ®Google Scholar
• Parrott N, Grimm HP, Fleury A, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica. 2007;37:1295–1310.
   PubMed Web of Science ®Google Scholar
• Ahmed SSSJ, Ramakrishna V. Systems biological approach of molecular descriptors connectivity: optimal descriptors for oral bioavailability prediction. PLoS One. 2012;7(7):1–10.
   Web of Science ®Google Scholar
• Kim MT, Sedykh A, Chakravarti SK, et al. Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches. Pharm Res. 2014;31:1002–1014.
   PubMed Web of Science ®Google Scholar
• Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 2009;5(3):259–293.
   PubMed Web of Science ®Google Scholar